Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

BACKGROUND: This analysis was carried out to evaluate the long-term survival of patients with metastatic melanoma who received ipilimumab, a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4, in clinical trials. PATIENTS AND METHODS: Patients received ipilimumab in one o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Wolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Cykowski, L., de Pril, V., Humphrey, R., Lebbé, C.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081656/
https://ncbi.nlm.nih.gov/pubmed/23666915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt161
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados